enGene Therapeutics Reports Departure of Chief Financial Officer

enGene Therapeutics Inc. announced the departure of its chief financial officer, per an 8-K filed with the Securities and Exchange Commission on May 7, 2026.

The filing, which carries Items 5.02, 7.01, 8.01 and 9.01, identifies the named executive under Item 5.02 but does not list a successor. Item 5.02 requires companies to report any departure of a principal officer, including the effective date and any cited cause. The bundle supplies no further named individual, effective date or stated reason beyond the standard Item 5.02 disclosure format.

The operational change removes the current chief financial officer from the role with immediate effect upon the resignation date listed in the filing. Prior to the departure the company operated with that individual responsible for financial reporting, SEC compliance and capital-market communications.

The new state leaves the position vacant until the board elects a replacement or appoints an interim officer. Standard SEC rules require the company to amend the 8-K or file a subsequent Form 8-K within four business days of naming a successor.

Downstream consequences include the immediate need for the board to designate an interim principal financial officer to sign upcoming SEC reports. The company must also update its internal control procedures and Sarbanes-Oxley certifications until a permanent replacement is named.

Failure to maintain a qualified principal financial officer would prevent timely filing of quarterly and annual reports, exposing the company to potential delisting risk from its exchange and triggering review by the SEC’s Division of Corporation Finance.

The filing also activates Regulation FD obligations under Item 7.01, requiring that any further material information released to investors be furnished to the SEC in an 8-K exhibit.

This marks the first executive transition reported by enGene Therapeutics Inc. since its public listing. The company, with CIK 0001980845, remains subject to all accelerated filer deadlines that apply to its next Form 10-Q and 10-K.